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Potentially inappropriate prescribing in Australian nursing home 
residents with advanced dementia: a sub-study of the IDEAL Study 
Potentially inappropriate prescribing in advanced dementia 
Abstract 
Background Prescribing medications for nursing home residents with advanced dementia should focus 
on optimising function and comfort, reducing unnecessary harms and aligning care goals with a 
palliative approach. 
Objective To estimate the proportion of Australian nursing home residents with advanced dementia 
receiving potentially inappropriate medications, identify those most commonly prescribed, and 
factors associated with their use. 
Design Data were collected through retrospective audit of medication charts. 
Setting/Subjects Two hundred and eighteen nursing home residents with advanced dementia from 20 
nursing homes participating in a cluster randomised controlled trial of case conferencing (the IDEAL 
Study) from June 2013 to December 2014. 
Measurements Inappropriate drug use was defined as medications classified as ‘never appropriate’ by 
the Palliative Excellence in Alzheimer Care Efforts program (PEACE) criteria. Generalized linear mixed 
models were used to identify variables predicting use of ‘never’ appropriate medications. 
Results Over a quarter (n= 65, 30%) of residents received at least one medication classed as ‘never’ 
appropriate, the most common being lipid-lowering agents (n=38, 17.4%), antiplatelet agents (n=18, 
8.3%) and acetylcholinesterase inhibitors (n=16, 7.3%). Residents who had been at the nursing home 
for ≤10 months (odds ratio [OR] 5.60, 95% confidence intervals [CI] 1.74-18.06), and 11 to 21 months 
(OR 5.41, CI 1.67-17.75) had significantly greater odds of receiving a never appropriate medication 
compared to residents who had been at the nursing home for >5 years. 
Conclusions Use of potentially inappropriate medications in Australian nursing home residents with 
advanced dementia is common. A greater understanding of the rationale that underpins prescribing 
of medications is required. 
Keywords 
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Introduction 
A palliative approach is best practice for people with advanced dementia. Their care and comfort 
should focus on minimising suffering.1, 2 The role of medications in a palliative approach is primarily to 
relieve symptoms and are prescribed when adverse effects are outweighed by the likelihood of 
benefits that fall within the individual’s life expectancy and no non-pharmacological alternatives are 
available3. Adverse effects associated with potentially inappropriate prescribing in older adults are 
associated with increased hospitalisation and mortality4, 5 and involves extensive costs to healthcare 
systems.6, 7 People with advanced dementia are particularly vulnerable to adverse drugs reactions as 
they undergo extreme physiological changes (in addition to those of normal ageing) that affect the 
way medications are metabolised in the body.8-10 
Whilst there are several criteria available for assessing the appropriateness of prescribing in the 
elderly,11 these are not readily applicable to a palliative approach to prescribing in advanced 
dementia.12 A recent systematic review identified only one currently available dementia-specific 
criteria for identifying potentially inappropriate medications, which were developed through the 
Palliative Excellence in Alzheimer Care Efforts Program (PEACE)13 and classify medications as ‘never’, 
‘rarely’, ‘sometimes’ or ‘always’ appropriate based on a Delphi process carried out with 12 
geriatricians.14 
Six international studies have used these criteria to examine the prevalence of inappropriate 
prescribing in nursing home residents with advanced dementia and associated factors.15-20 These 
studies were undertaken in European countries,17-19 the USA15, 16 and Canada,20 and found that 
proportions of nursing home residents with advanced dementia receiving ‘never’ appropriate 
medications ranged from 3%17 to 45%20 of study populations. Lipid-lowering agents,15, 16, 18, 20 
antiplatelet agents,17, 18, 20 antihypertensives,17 and anti-dementia drugs, specifically 
acetylcholinesterase inhibitors15, 16, 18, 20 and memantine,15 were found to be the most commonly 
prescribed ‘never’ appropriate medications. Predictors found to be associated with receiving ‘never’ 
appropriate medications included male gender,16 a higher functional status,16 earlier stage 
dementia,16, 20 a shorter length of stay at the nursing home,16 diabetes, 16, 20 having had a stroke,18, 20 
living in a nursing home with frequent use of feeding tubes,15 and receiving high numbers of 
medications.20 
To date, there have been two studies estimating the prevalence of inappropriate prescribing in 
Australian nursing home residents with dementia.21, 22 Bosboom et al (2012) included residents at 
varying stages of dementia progression and used general-elderly measures of potentially 
inappropriate prescribing [Beers criteria, Drug Burden Index (>0) and polypharmacy (≥5 medications)] 
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rather than dementia-specific or palliative-specific criteria. Somers et al (2010) also used the Beers 
criteria to determine appropriateness of medications in their sample of residents with dementia. 
More recently, a new set of delphi constructed guidance measures have been developed by Australian 
experts to help guide clinicians who manage co-morbid conditions in people with dementia.23 The 
authors also further externally validated these guidance statements in focus groups with health 
professionals to determine their utility in clinical practice.24 However, these guidance measures have 
not been designed to identify the prevalence of potentially inappropriate medications via chart audit. 
The current project aimed to estimate the prevalence of potentially inappropriate prescribing in 
Australian nursing home residents with advanced dementia, using the disease- and stage-specific 
PEACE criteria. Specific objectives were to identify: 1) the proportion of residents taking ‘never’ 
appropriate medications, 2) the most commonly prescribed ‘never’ appropriate medications, and 3) 
factors associated with an increased likelihood of residents receiving ‘never’ appropriate medications. 
Methods 
Study design 
This research formed a sub-study of a cluster randomised controlled trial (RCT) of facilitated case 
conferencing for residents with advanced dementia living in 20 nursing homes in Sydney and Brisbane, 
Australia (the ‘IDEAL Study’).25 The sub-study used a retrospective medication chart audit. 
Ethics approval 
Approval to undertake this research was obtained from the University of New South Wales Human 
Research Ethics Committee (approval number HC12455). Because individuals with advanced dementia 
lack capacity to provide informed consent, ethics approval was gained for proxy consent by a family 
member. Medication data were collected from June 2013 to December 2014. 
Study population 
Nursing homes 
Nursing homes were eligible to participate in the IDEAL Study if they were located in the greater 
metropolitan areas of Sydney or Brisbane and met the following criteria: 1) ≥100 high care beds and 
2) ≥50% residents with dementia (or equivalent number of residents with dementia achieved by a 
higher proportion or residents with dementia but lower number of beds). 
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To minimise selection bias, eligible nursing homes were identified via the Aged Care Australia website 
(recently superseded by http://www.myagedcare.gov.au/) and approached in random order until the 
target sample size of 20 was achieved. 
Residents 
To be eligible for the IDEAL Project, residents needed to have: 1) dementia status reported in their 
progress notes and level of cognitive impairment stable for ≤1 month according to residential aged 
care staff; 2) advanced dementia as determined by screening using the Functional Assessment Staging 
Tool (FAST)26 of ≥6a; and an Australia–modified Karnofsky Performance Status (AKPS)27 score of ≤50; 
3) availability of a person legally responsible to give consent on their behalf; and 4) informed consent 
from a family member or other who knew the resident well and was willing to participate in IDEAL to 
report their perception of quality of care. Criterion 2 was chosen because dementia stage and 
functioning are predictive of <6 months survival28 and the IDEAL Project’s primary endpoint related to 
end-of-life care. 
Data collection 
Socio-demographic and clinical data 
Wherever available and relevant to the Australian setting, data for the current analyses used variables 
found by previous studies to be significantly predictive of ‘never’ appropriate prescribing as defined 
by the PEACE criteria.15-18 These included gender16, length of stay at the nursing home,16 functional 
status16, dementia status,16 diabetes16 and stroke.18 
Significant predictors found in two studies19, 20 utilising similar approaches to Holmes et al 2008 were 
excluded from analysis for the following reasons. Differences in the way Parsons et al (2015) 
categorised medications from Holmes et al include reaching consensus for aspirin, iron, vitamins, 
mineral supplements and finasteride, and placing them under the ‘never’ appropriate category.19 
Parsons et al’s criteria also deviated from Holmes et al by placing acetylcholinesterase inhibitors under 
‘rarely’ appropriate and memantine under ‘sometimes’ appropriate, both of which were under ‘never’ 
appropriate in the PEACE criteria. We chose not to include Parsons et al as a source study because of 
these medication classification differences, and because they used a small sample of only 15 residents. 
Matlow et al 2017 focused their analysis on the last week of life, making their sample incomparable 
to our own. 
Data on dementia stage and functional status collected at baseline were used for this sub-study’s 
analysis and were collected using the FAST and AKPS respectively. All other data were collected from 
administrative and nursing records kept at each nursing home. 
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The FAST divides progression of dementia into seven distinct stages based on observable cognitive 
and behavioural symptoms. The observational nature of the FAST enables it to be used to assess 
moderate-severe stages of dementia when cognitive tests such as the Mini Mental State Examination 
(MMSE)29 no longer provide useful information. 
The AKPS assigns a single score between 0 (dead) and 100 (normal; no complaints; no evidence of 
disease) based on observation of functional independence. A score of 50, the maximum at which a 
resident was deemed eligible for the current study, indicates that a person ‘requires considerable 
assistance and frequent medical care’. 
Resident variables found to be predictive of ‘never’ appropriate prescribing by previous studies but 
either not relevant to the Australian setting or unavailable in the IDEAL Study dataset were African-
American ethnicity,15 and hospitalizations in the last 90 days15 respectively. Use of feeding tubes was 
found predictive in one previous study,15 however none of the residents participating in the IDEAL 
study was using a feeding tube. Nursing home variables found predictive that had no variability in the 
IDEAL Study sample were dementia specificity,15 metropolitan status15 and facility-level use of feeding 
tubes; all nursing homes participating in the IDEAL Study included high proportions of residents with 
dementia, were metropolitan and had equally low proportions of residents using feeding tubes. 
Medication charts 
To increase reliability, data collection and coding was undertaken via a standardised approach 
maintained for all residents in all nursing homes, leaving little room for error or variation in 
investigator interpretation.30 Medication charts were reviewed for each resident and names extracted 
as written. This sub-study focused on regularly prescribed medications because of the difficulty in 
deducing burden from pro re nata (PRN) and short-term medications. 
Medication chart data were entered into Microsoft Excel version 10 (Microsoft Corporation, Seattle) 
using study numbers to identify each resident. Medications were then coded according to the 
Anatomical Therapeutic Chemical (ATC) Classification System, an international standard for drug 
utilisation studies recognised by the World Health Organisation31 and used extensively in literature to 
categorise medications. 
Once ATC codes had been allocated to each medication, these were then classified according to PEACE 
criteria for ‘never’ appropriate prescribing, adopting the codes reported by Toscani et al (2013)17 (see 
Box 1). 
Box 1. Medications defined as ‘never’ appropriate for people with advanced dementia based on a 
consensus process and with ATC codes allocated by Toscani et al (2013) 17 
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Antiplatelet agents, excluding Aspirin (B01AC excl B01AC06); Lipid-lowering medications (C10); Sex 
hormones (G03H); Cytotoxic chemotherapy (L01); Hormone antagonists (L02B); Antiestrogens 
(L02BA; L02BB); Immunomodulators (L03); memantine (N06DX01); Acetylcholinesterase inhibitors 
(N07AA); Leucotriene receptor antagonists (R03DC) 
Medications with ATC code N06D were included to this study’s classification of ‘never’ appropriate 
acetylcholinesterase inhibitors. 
While we used the same codes previously selected by Toscani et al, there was one exception where 
they included N06D acetylcholinesterase inhibitors into the ‘always’ appropriate category, possibly 
due to the recent evidence showing effectiveness in severe dementia. However, we chose to include 
these medications under the ‘never’ appropriate category, as the safety and benefit of these 
medications for individuals receiving palliative care is still contentious. 
Statistical analyses 
Descriptive analyses were conducted to provide summary characteristics for residents. A chi-square 
analysis was conducted to test whether there was a significant difference in the percentages of 
residents taking a ‘never’ appropriate medication between intervention and control groups. Where 
no significant difference was observed, it was considered appropriate to combine the arms for all 
further analyses. 
Generalized Linear Mixed Models (GLMM) with a logit link function were used to determine predictors 
of receiving a ‘never’ appropriate medication (binomial distribution). GLMMs allow for the inclusion 
of fixed and random effects in the model, and allow for nested sources of variability in data. In these 
models, the nursing home was included as a random effect, to account for the intra cluster-
correlations in the sample and produce better fixed-effect estimates. 
A preliminary GLMM included all variables found in previous studies as predictors of residents with 
advanced dementia receiving a ‘never’ appropriate medication; these variables included gender, 
length of stay at the nursing home (categorised into quintiles), functional status (AKPS score), 
dementia status (FAST score 7 vs 6), diabetes and stroke. The final model included only factors 
significant (p<0.05) or approaching significance (p<0.2) in the first analysis. For each model, p-values 
were provided for each estimate of fixed effects, and odds ratio (OR) and 95% confidence interval 
(95%CI) were provided for each fixed coefficient. 
All analyses were conducted using SPSS (version 24) and p-values <0.05 considered to indicate 
statistical significance. 
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Results 
The IDEAL project recruited 13 nursing homes in Sydney and 7 in Brisbane. Nursing homes had a 
median of 115 beds (IQR 100 – 135), and 12 were private and 8 not for profit. Of the 286 residents 
recruited to the IDEAL project, we were able to collect not only complete medication data but also 
socio-demographic and clinical data for 218 residents, 110 residents from intervention nursing homes 
and 108 from nursing homes allocated to the control group. See Table 2 for sample characteristics. A 
chi-square analysis found no significant difference in the percentages of residents taking a ‘never’ 
appropriate medication between intervention and control groups (p=0.183), so the groups were 
combined for all further analyses. 
Table 1. Characteristics for 218 residents with advanced dementia 
Characteristics Whole sample 
(n = 218) 
At least one 
‘never’ 
appropriate 
medication 
(n = 65) 
All medications 
appropriate 
(n = 153) 
 n (%) n (%) n (%) 
Gender, female 135 (61.9) 34 (52.3) 101 (66.0) 
Length of stay at nursing home    
 ≤10 months 47 (21.6) 21 (32.3) 26 (17.0) 
 11-21 months 43 (19.7) 18 (27.7) 25 (16.3) 
 22-37 months 44 (20.2) 11 (16.9) 33 (21.6) 
 38-60 months 41 (18.8) 10 (15.4) 31 (20.3) 
 > 5 years 43 (19.7) 5 (7.7) 38 (24.8) 
AKPS    
 20 (totally bedfast) 40 (18.3) 6 (9.2) 34 (22.2) 
 30 42 (19.3) 13 (20.0) 29 (19.0) 
 40 49 (22.5) 13 (20.0) 36 (23.5) 
 50 (considerable assistance) 87 (39.9) 33 (50.8) 54 (35.3) 
FAST    
      6 (severe cognitive decline) 51 (23.4) 17 (26.2) 34 (22.2) 
      7 (very severe cognitive decline) 167 (76.6) 48 (73.8) 119 (77.8) 
Comorbidities     
 Stroke 27 (12.4) 6 (9.2) 21 (13.7) 
 Diabetes 29 (13.3) 12 (18.5) 17 (11.1) 
AKPS, Australia-modified Karnofsky Performance Status;27 FAST, Functional Assessment Staging 
Tool26 
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Prevalence of different medications 
Residents with advanced dementia were receiving an average of 7.3 (median 7.0, SD 3.5, range 0 - 21) 
regularly prescribed medications each. The most commonly prescribed medications types overall 
were laxatives (64.7%, n=141/218), simple analgesics (58.3%, n=127/218), vitamins (51.8%, 
n=113/218) and antipsychotics (46.8%, n=102/218). Out of the 218 residents included in the study, 65 
(29.8%) were receiving at least one medication rated ‘never’ appropriate by the PEACE criteria, with 
11 (5.0%) receiving more than one. The most commonly prescribed ‘never’ appropriate medications 
were lipid-lowering agents, antiplatelet agents and acetylcholinesterase inhibitors (see Table 2). 
Table 2. Summary of residents receiving ‘never’ appropriate medications, N=218 residents 
Medication type Number of residents receiving (% of total 
residents) 
 n (%) 
Lipid-lowering medications 38 (17.4) 
Antiplatelet agents 18 (8.3) 
Acetylcholinesterase inhibitors 16 (7.3) 
Memantine 6 (2.8) 
Cytotoxic chemotherapy 1 (0.5) 
Antiestrogens 1 (0.5) 
Hormone antagonists 1 (0.5) 
Predictors of ‘never’ appropriate medications  
Of factors associated with ‘never’ appropriate medications in previous studies, only shorter length of 
stay was found predictive in the current sample (F(4,206) = 2.61, p=0.037; Table 3). Residents who had 
been at the nursing home less than or equal to 10 months, or between 11 and 21 months, had 5 times 
greater odds of receiving a ‘never’ appropriate medication than residents who had been at the nursing 
home for 61+ months (>5 years). 
While functional status (AKPS) as an overall fixed effect was not found to be significant (F(3,206) = 
1.75, p=0.16), residents with AKPS 20 had significantly lower odds of receiving a ‘never’ appropriate 
medication compared to those with AKPS 50 (OR 0.33, 95%CI 0.11-0.98; see Table 3). 
Table 3: Preliminary model of associations of potential risk of receiving ‘never’ appropriate 
medications (N=218) 
 9 
 
Variable Categories OR  95% CI P Value 
Sex Male 1.102  0.729, 2.813 0.295 
Female -   
Length of 
Stay 
    0.037 
≤ 10 months 5.349 1.600, 17.879 0.007 
11-21 months 5.624 1.673, 18.911 0.005 
22-37 months 2.866 0.826, 9.937 0.097 
38-60 months 2.459 0.705, 8.582 0.157 
> 5 years -   
AKPS    0.158 
20 0.329 0.110, 0.980 0.046 
30 1.088 0.423, 2.797 0.861 
40 0.625 0.253, 1.545 0.308 
50 -   
FAST Score 6 1.015  0.296, 1.483 0.315 
Score 7 -   
Stroke No 1.218  0.418, 3.547 0.716 
Yes -   
Diabetes No 0.482  0.191, 1.214 0.121 
Yes -   
AKPS, Australia-modified Karnofsky Performance Status27 (lower scores indicate greater assistance 
required); FAST, Functional Assessment Staging Tool26 (higher scores indicate greater functional 
deterioration); CI, confidence interval; OR, odds ratio. Reference categories indicated by ‘-‘. The p-
values correspond to the fixed effects F statistics. The results are based on the generalized linear mixed 
effect model (GLMM) analysis with nursing home as a random effect. Statistically significant odds 
ratios are in bold (P<0.05) 
Table 4 shows the results of the final GLMM model which included length of stay, functional status 
(AKPS) and diabetes. Length of stay continued to be the only significant predictor of receiving a ‘never’ 
appropriate medication (F(4,209) = 2.84, p = 0.025). 
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Table 4:  Final model of associations of potential risk of receiving ‘never’ appropriate medications 
(N=218) 
Variable Categories OR  95% CI P Value 
Length of 
Stay 
   0.025 
≤ 10 months 5.599 1.736, 18.055 0.004 
11-21 months 5.411 1.666, 17.750 0.005 
22-37 months 2.836 0.838, 9.592 0.093 
38-60 months 2.415 0.708, 8.242 0.158 
> 5 years -   
AKPS    0.221 
20 0.375 0.132, 1.067 0.066 
30 1.101 0.454, 2.667 0.831 
40 0.662 0.285, 1.538 0.335 
50 -   
Diabetes No 0.445 0.181, 1.093 0.077 
Yes -   
AKPS, Australia-modified Karnofsky Performance Status27 (lower scores indicate greater assistance 
required); FAST, Functional Assessment Staging Tool26 (higher scores indicate greater functional 
deterioration); CI, confidence interval; OR, odds ratio. The p-values correspond to the fixed effects F 
statistics. The results are based on the generalized linear mixed effect model (GLMM) analysis with 
nursing home as a random effect. Statistically significant odds ratios are in bold (P<0.05) 
Discussion 
This study is the first to estimate prevalence of potentially inappropriate prescribing in Australian 
nursing home residents with advanced dementia using the PEACE criteria, an explicit disease- and 
stage-specific criteria. Nursing home residents in the current study were taking an average of seven 
medications, with nearly one third receiving at least one medication rated ‘never’ appropriate. Similar 
to previous studies, lipid-lowering agents,15, 16, 18 antiplatelet agents15, 17, 18 and acetylcholinesterase 
inhibitors15, 16, 18 were the most commonly prescribed ‘never’ appropriate medications. Our data also 
replicate previous findings that a shorter length of stay16, 18 is a significant predictor for receiving one 
or more ‘never’ appropriate medications, highlighting the need for medication review shortly after a 
resident’s admission to ensure medications are consistent with a palliative approach where 
 11 
 
appropriate.Two studies have identified an association between inappropriate medication use and 
higher functional status.15, 32 While our study did not find an overall association between functional 
status (AKPS score) and receiving ‘never’ appropriate medications, our results trended towards the 
same direction, with residents who had a lower functional status (AKPS 20, totally bedfast) being 
significantly less likely than those with the highest functional status (AKPS 50, requiring considerable 
assistance and frequent medical care) to receive a ‘never’ appropriate medication. 
The finding that a shorter length of stay increases the odds of receiving ‘never’ appropriate 
medications in residents with advanced dementia may suggest that a longer stay allows for more time 
for conversations to be had  with substitute decision makers regarding goals of care, and a rationale 
developed for stopping medications where applicable. This finding may also highlight the need for 
medication review early on or even at the time of a resident’s admission to ensure medications are 
consistent with a palliative approach. 
No significant change in odds of receiving inappropriate medications between residents with higher 
and lower cognitive and functional status is troubling as it suggests recommended monitoring, review 
and deprescribing of unnecessary medications as end of life approaches may not yet be a common 
practice of medication management in residents with advanced dementia. 
The proportion of residents (29.8%) taking ‘never’ appropriate drugs in the current study was lower 
than those in similar studies undertaken in the US (37%, 54%),15, 16 similar to that found in a pan-
European study (27%),18 and higher than that reported in a study exclusively undertaken in Italy (3%).17 
These inconsistencies may be due to differences in prescribing cultures between countries or 
differences in the ways studies sampled nursing homes and residents. 
Rationalising the use of ‘never’ appropriate medications like lipid-lowering agents and antiplatelet 
agents is difficult. Their therapeutic goal to reduce vascular events and mortality becomes irrelevant 
in a population where maintaining comfort rather than extending life is the focus, and time to benefit 
almost certainly exceeds the person’s life span. Both pose risks of adverse effects, including abdominal 
pain, constipation and nausea for lipid-lowering agents,33, 34 and haemorrhage of the gastrointestinal 
tract for antiplatelet agents.35 Australian clinical practice guidelines36, 37 provide recommendations on 
the rational use and deprescribing acetylcholinesterase inhibitors and memantine. While these 
medications may be appropriate for people with advanced dementia under some circumstances, 
evidence of their benefits is limited 38, 39 and has been met with criticism.40 They also have side-effects 
including nausea, vomiting, diarrhoea and muscle cramps.41 
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The high rates of residents prescribed antipsychotics (47%) is much higher than previously reported 
in studies in other countries15-17 which range from 27%16 to 30%.17 Whilst classed as ‘sometimes’ rather 
than ‘never’ appropriate by the PEACE criteria, a report by Alzheimer’s Australia (2014) recommended 
the use of antipsychotics should be time limited and reviewed regularly with multidisciplinary input 
from pharmacists, behaviour management experts, GPs and psychiatrists.32 
As well as identifying high rates of medicines of concern, our study found that laxatives (65%) and 
simple analgesics (58%) were the most commonly prescribed medications overall. Rates of analgesic 
use were similar to results from US studies (58%16 and 59%15) and substantially higher than rates in 
the Italian study (8.1%17). While our analysis did not examine the reasons for prescription, higher rates 
of analgesic and laxative use are generally encouraging given evidence that symptoms often go 
unrecognised and under-treated in this population.42-44 
Limitations 
The limitations of this study arise from data being collected via retrospective chart audit, its 
dependence on a single method (the PEACE criteria) of identifying inappropriate prescribing, and its 
status as an RCT sub-study. Problems relating to retrospective chart audits identified in the literature 
include a lack of standardisation in chart formats utilised, incomplete records and illegibility.45 The 
current study sought to minimise these problems by using residents’ medication chart as the primary 
source of data – charts that are required to be up-to-date and legible for regular use and surveillance. 
However, an exclusive focus on medication charts meant the study lacked information on the reasons 
‘never’ appropriate medications had been prescribed and had not been withdrawn. Even a detailed 
review of progress notes and clinical assessments would have been unlikely to inform understanding 
of appropriateness for each resident given variability in the quality of reporting and long duration of 
prescription in many cases, for some residents even prior to admission. The PEACE criteria categories 
offer a ‘one size fits all’ approach to identifying inappropriate medications and do not take into 
account clinical factors and context that may be at play in individual cases. Holmes et al (2008) 
identified a need for future research focusing on larger sample populations which can better showcase 
the relationship between comorbidities and medication use, as well as identify distinct medication 
classes that may be overused14. Dependence on IDEAL Study data meant that some variables found 
predictive by previous studies (especially those at the nursing home level) could not be included in the 
current analyses. Also, the nursing homes involved in the RCT may have been more aware of issues 
relating to inappropriate prescribing than the industry average. Twenty two percent of residents in 
the intervention arm (11% of the total sample) had their medication charts collected after the 
intervention commenced at their nursing home, raising the possibility that the intervention may have 
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influenced prescribing, even though this was not of a magnitude that led to a significant difference in 
the number of residents taking ‘never’ appropriate medications in each arm. These factors mean that 
our results may have underestimated the prevalence of inappropriate prescribing in Australian nursing 
homes more generally. Finally, our study shares a limitation with those previous in not exploring the 
risk and seriousness of adverse effects from being prescribed a never appropriate medication. More 
research is needed to establish the clinical outcomes of such prescriptions in nursing home residents 
with advanced dementia. 
Conclusion 
To our knowledge, this is the first Australian study to estimate the prevalence of inappropriate 
prescribing in nursing home residents with advanced dementia using a disease- and stage- specific 
tool. Our results indicate that a significant minority of residents may be taking inappropriate 
medications including lipid-lowering medications, antiplatelet agents and acetylcholinesterase 
inhibitors.  These findings are limited by use of only one set of criteria for identifying inappropriate 
medications and the lack of detailed clinical data to contextualise prescribing for each individual 
resident. More research is needed to guide deprescribing of these medicines, and the associated 
negative outcomes of their use in advanced dementia.  
Acknowledgments 
We would like to acknowledge the IDEAL Study project team for their assistance in collecting the data 
in this sub-study, including Janet Cook, Deborah Brooks, Priyanka Bhattarai, Huali (Molly) Cao and Dr 
Jennifer Houltram. 
Author Disclosure Statement 
The IDEAL Study was funded by the Australian Department of Health (previously Department of 
Health and Ageing). DD was provided a PhD scholarship from the University of Technology Sydney. 
All other authors have no potential conflicts of interest that are directly relevant to the content of 
this study. 
Authors’ Contribution 
DD, TL, PMD, SB and MA contributed to design of the research. DD carried out the data acquisition 
and analysis. GL advised on statistical analysis. TL and MA were involved in interpretation of results. 
All authors contributed to writing the report and approved the final manuscript.  
 14 
 
References 
1. Mitchell SL, Teno JM, Kiely DK, Shaffer ML, Jones RN, Prigerson HG, et al. The clinical course 
of advanced dementia. New England Journal of Medicine. 2009;361(16):1529-38. 
2. Agar M, Beattie E, Luckett T, Phillips J, Luscombe G, Goodall S, et al. Pragmatic cluster 
randomised controlled trial of facilitated family case conferencing compared with usual care for 
improving end of life care and outcomes in nursing home residents with advanced dementia and 
their families: the IDEAL study protocol. BMC palliative care. 2015;14(1):63. 
3. Stevenson J, Abernethy AP, Miller C, Currow DC. Managing comorbidities in patients at the 
end of life. BMJ. 2004;329(7471):909-12. 
4. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse 
drug events in older Americans. New England Journal of Medicine. 2011;365(21):2002-12. 
5. Kalisch LM, Caughey GE, Barratt JD, Ramsay EN, Killer G, Gilbert AL, et al. Prevalence of 
preventable medication-related hospitalizations in Australia: an opportunity to reduce harm. 
International Journal for Quality in Health Care. 2012;24(3):239-49. 
6. Cahir C, Fahey T, Teeling M, Teljeur C, Feely J, Bennett K. Potentially inappropriate 
prescribing and cost outcomes for older people: a national population study. Br J Clin Pharmacol. 
2010;69(5):543-52. 
7. Hovstadius B, Petersson G. The impact of increasing polypharmacy on prescribed drug 
expenditure—a register-based study in Sweden 2005–2009. Health Policy. 2013;109(2):166-74. 
8. Parsons C, Hughes CM, Passmore AP, Lapane KL. Withholding, discontinuing and 
withdrawing medications in dementia patients at the end of life: a neglected problem in the 
disadvantaged dying? Drugs Aging. 2010;27(6):435-49. 
9. Lau DT, Mercaldo ND, Harris AT, Trittschuh E, Shega J, Weintraub S. Polypharmacy and 
potentially inappropriate medication use among community-dwelling elders with dementia. 
Alzheimer Dis Assoc Disord. 2010;24(1):56-63. 
10. Riker GI, Setter SM. Polypharmacy in older adults at home: what it is and what to do about 
it--implications for home healthcare and hospice. Home Healthc Nurse. 2012;30(8):474-85; quiz 86-
7. 
11. Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck JC. Explicit criteria for 
determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric 
Medicine. Archives of Internal Medicine. 1991;151(9):1825-32. 
12. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria 
for potentially inappropriate medication use in older adults: results of a US consensus panel of 
experts. Archives of Internal Medicine. 2003;163(22):2716. 
13. Holmes HM, Sachs GA, Shega JW, Hougham GW, Cox Hayley D, Dale W. Integrating palliative 
medicine into the care of persons with advanced dementia: identifying appropriate medication use. 
Journal of the American Geriatrics Society. 2008;56(7):1306-11. 
14. Disalvo D, Luckett T, Agar M, Bennett A, Davidson PM. Systems to identify potentially 
inappropriate prescribing in people with advanced dementia: a systematic review. BMC geriatr. 
2016;16(1):114. 
15. Tjia J, Briesacher BA, Peterson D, Liu Q, Andrade SE, Mitchell SL. Use of medications of 
questionable benefit in advanced dementia. JAMA internal medicine. 2014;174(11):1763-71. 
16. Tjia J, Rothman MR, Kiely DK, Shaffer ML, Holmes HM, Sachs GA, et al. Daily medication use 
in nursing home residents with advanced dementia. Journal of the American Geriatrics Society. 
2010;58(5):880-8. 
17. Toscani F, Di Giulio P, Villani D, Giunco F, Brunelli C, Gentile S, et al. Treatments and 
prescriptions in advanced dementia patients residing in long-term care institutions and at home. 
Journal of Palliative Medicine. 2013;16(1):31-7. 
18. Colloca G, Tosato M, Vetrano DL, Topinkova E, Fialova D, Gindin J, et al. Inappropriate drugs 
in elderly patients with severe cognitive impairment: results from the shelter study. PloS one. 
2012;7(10):e46669. 
 15 
 
19. Parsons C, McCann L, Passmore P, Hughes C. Development and application of medication 
appropriateness indicators for persons with advanced dementia: a feasibility study. Drugs & aging. 
2015;32(1):67-77. 
20. Matlow JN, Bronskill SE, Gruneir A, Bell CM, Stall NM, Herrmann N, et al. Use of Medications 
of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia. 
Journal of the American Geriatrics Society. 2017. 
21. Bosboom PR, Alfonso H, Almeida OP, Beer C. Use of potentially harmful medications and 
health-related quality of life among people with dementia living in residential aged care facilities. 
Dementia and geriatric cognitive disorders extra. 2012;2(1):361-71. 
22. Somers M, Rose E, Simmonds D, Whitelaw C, Calver J, Beer C. Quality use of medicines in 
residential aged care. Aust Fam Physician. 2010;39(6):413-6. 
23. Page AT, Clifford RM, Potter K, Schwartz D, Etherton‐Beer CD. The feasibility and effect of 
deprescribing in older adults on mortality and health: a systematic review and meta‐analysis. Br J 
Clin Pharmacol. 2016;82(3):583-623. 
24. Page AT, Clifford RM, Potter K, Seubert L, McLachlan AJ, Hill X, et al. Exploring the enablers 
and barriers to implementing the Medication Appropriateness Tool for Comorbid Health conditions 
during Dementia (MATCH-D) criteria in Australia: a qualitative study. BMJ open. 2017;7(8):e017906. 
25. Agar M, Luckett T, Luscombe G, Phillips J, Beattie E, Pond D, et al. Effects of facilitated family 
case conferencing for advanced dementia: A cluster randomised clinical trial. PLOS ONE. 
2017;12(8):e0181020. 
26. Reisberg B. Functional Assessment Staging (FAST). Psychopharmacology Bulletin 1988. 
1988;24:653-9. 
27. Abernethy AP, Shelby-James T, Fazekas BS, Woods D, Currow DC. The Australia-modified 
Karnofsky Performance Status (AKPS) scale: a revised scale for contemporary palliative care clinical 
practice [ISRCTN81117481]. BMC palliative care. 2005;4(1):7. 
28. Coventry PA, Grande GE, Richards DA, Todd CJ. Prediction of appropriate timing of palliative 
care for older adults with non-malignant life-threatening disease: a systematic review. Age Ageing. 
2005;34(3):218-27. 
29. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading 
the cognitive state of patients for the clinician. Journal of Psychiatric Research. 1975;12(3):189-98. 
30. Grimes DA, Schulz KF. Bias and causal associations in observational research. The Lancet. 
2002;359(9302):248-52. 
31. WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC Classification 
and DDD Assignment 2013. 2013. 
32. Alzheimer's Australia. The Use of Restraints and Psychotropic Medications in People with 
Dementia: A Report For Alzheimer's Australia. 2014. 
33. Hilmer S, Gnjidic D. Statins in older adults. Australian Prescriber. 2013. 
34. Armitage J. The safety of statins in clinical practice. The Lancet. 2007;370(9601):1781-90. 
35. Salvi F, Marchetti A, D’Angelo F, Boemi M, Lattanzio F, Cherubini A. Adverse drug events as a 
cause of hospitalization in older adults. Drug Saf. 2012;35(1):29-45. 
36. Clinical Practice Guidelines for Dementia in Australia. 2015. 
37. Reeve E, Farrell B, Thompson W, Herrmann N, Sketris I, Magin P, et al. Evidence-based 
Clinical Practice Guideline for Deprescribing Cholinesterase Inhibitors and Memantine in People with 
Dementia. 
38. Winblad B, Kilander L, Eriksson S, Minthon L, Båtsman S, Wetterholm A-L, et al. Donepezil in 
patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study. The 
Lancet. 2006;367(9516):1057-65. 
39. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, et al. Donepezil and 
memantine for moderate-to-severe Alzheimer's disease. New England Journal of Medicine. 
2012;366(10):893-903. 
 16 
 
40. Suzuki T, Howard R, McShane R, Lindesay J. Discontinuing Donepezil or Starting Memantine 
for Alzheimer's Disease. The New England journal of medicine. 2012;366(23):2227. 
41. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's 
disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 
and Geriatric Cognitive Disorders. 1996;7(6):293-303. 
42. Bayer A. Death with dementia—the need for better care. Age and Ageing. 2006;35(2):101-2. 
43. Chang E, Daly J, Johnson A, Harrison K, Easterbrook S, Bidewell J, et al. Challenges for 
professional care of advanced dementia. International Journal of Nursing Practice. 2009;15(1):41-7. 
44. McAuliffe L, Nay R, O’Donnell M, Fetherstonhaugh D. Pain assessment in older people with 
dementia: literature review. Journal of Advanced Nursing. 2009;65(1):2-10. 
45. Jansen AC, van Aalst-Cohen ES, Hutten BA, Büller HR, Kastelein JJ, Prins MH. Guidelines were 
developed for data collection from medical records for use in retrospective analyses. Journal of 
clinical epidemiology. 2005;58(3):269-74. 
 
